NuVasive price target raised to $30 from $25 at ThinkEquity

theflyonthewall.com

After conducting checks, ThinkEquity reports that the spine market remains challenged but stable. The firm believes that NuVasive is poised to report stronger than expected Q2 results, and it maintains a Buy rating on the stock.

View Comments (0)